11/10/2018 22:48:25

CLASS ACTION UPDATE for ABBV, MGTI and SFIX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Related content
21 Nov - 
The Klein Law Firm Reminds Investors of Class Actions o..
20 Nov - 
DEADLINE TODAY: The Schall Law Firm Announces the Filin..
18 Nov - 
SHAREHOLDER ALERT: TGTX ABBV MGTI HAS CPB CHGG ADNT GOO..

NEW YORK, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

AbbVie Inc. (NYSE: ABBV)

Class Period: October 25, 2013 - September 18, 2018

Lead Plaintiff Deadline: November 20, 2018

Join the action: https://www.zlk.com/pslra-1/abbvie-inc-loss-form?wire=3

The lawsuit alleges: AbbVie Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

To learn more about the AbbVie Inc. class action contact jlevi@levikorsinsky.com.

MGT Capital Investments Inc. (OTCMKTS: MGTI)

Class Period: October 9, 2015 - September 7, 2018

Lead Plaintiff Deadline: November 27, 2018

Join the action: https://www.zlk.com/pslra-1/mgt-capital-investments-inc-loss-form?wire=3

The lawsuit alleges: MGT Capital Investments Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in an illegal pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (2) the "Scheme Defendants"--Defendants Ladd, Honig, Stetson, Brauser, O’Rourke, and Groussman--had a history of engaging in illegal conduct in connection with the purchase and sale of securities; (3) the Scheme Defendants were a “group”, pursuant to Section 13 of the Exchange Act; (4) the Scheme Defendants exercised control over the Company; (5) the Company’s acquisition of D-Vasive Inc. was part of Defendants’ illegal pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (6) Defendants’ illicit scheme caused MGT Capital to make false and misleading statements, which would result in governmental and regulatory scrutiny; (7) the scheme would result in the delisting of MGT Capital’s stock from NYSE MKT; and (8) as a result, Defendants’ statements about MGT Capital’s business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the MGT Capital Investments Inc. class action contact jlevi@levikorsinsky.com.

Stitch Fix, Inc. (NASDAQ: SFIX)

Class Period: June 8, 2018 - October 1, 2018

Lead Plaintiff Deadline: December 10, 2018

Join the action: https://www.zlk.com/pslra-1/stitch-fix-inc-loss-form?wire=3

The lawsuit alleges: Stitch Fix, Inc. made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) Stitch Fix’s active client growth had slowed to a crawl; (2) Stitch Fix had completely shut down its television advertising campaign for 10 of the 13 weeks in fourth quarter 2018, dramatically decreasing the number of new active client additions; and (3) as a result, the Company’s current business metrics and financial prospects were not as strong as it had led the market to believe during the Class Period.

To learn more about the Stitch Fix, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Toll Free: (877) 363-5972

Fax: (212) 363-7171

www.zlk.com

250x148_zlk.jpg

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
2
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
3
Uptick Newswire’s Stock Day Podcast Hosts Medifocus, Inc.’s CEO to Discuss Their Minimally Invasive Breakthrough Treatments for Prostate and Breast Cancers
4
WISeKey Secures Printer Systems, from Cartridge to Cloud, with WISePrint@Cloud
5
Flame Seal Products FS-PG Wildfire Protection System Proves Totally Effective in Raging California Wildfire

Related stock quotes

AbbVie Inc 87.61 0.7% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
11 December 2018 03:14:25
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB7 - 2018-12-11 04:14:25 - 2018-12-11 03:14:25 - 1000 - Website: OKAY